Unexpected results in cancer drug trial

Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.

The New EPOC study, published in The Lancet Oncology and funded by Cancer Research UK, evaluated whether the drug and together worked better than chemotherapy alone as a treatment in addition to surgery for people with bowel cancer that had spread to the liver but could be surgically removed. In the trial either received chemotherapy on its own or chemotherapy combined with cetuximab. Patients received their specified treatment for 12 weeks. They then had surgery and followed by their specified treatment for another 12 weeks. Patients were then monitored via CT or MRI scans.

The researchers found that adding cetuximab to chemotherapy did not help this group of people. Analysis looked at how long people in each group were living without any sign of their cancer getting worse. They found this was on average 14.1 months in the group having chemotherapy and cetuximab compared to 20.5 months in the group having chemotherapy alone.

John Primrose, Professor of Surgery at the University of Southampton, comments: "These results were unexpected. Cetuximab is already approved by NICE alongside chemotherapy for people who had that had spread to the liver if the oncologist and liver surgeon thought this would enable the patient to have a liver operation. The cetuximab and is also used successfully in patients whose disease cannot be operated on at all. Our trial tested it in people who had cancer spread to the liver who were suitable for surgery from the outset, a similar group, but for these patients it seems to have an adverse effect. More research is needed to understand this surprising result."

Professor Primrose, also a consultant surgeon at Southampton General Hospital, adds: "These are very important data and we would like to thank the patients and relatives of patients those who took part in this trial, as well as the many clinicians in the UK who participated. Our results demonstrate the importance of clinical trials to ensure patients with cancer receive the best of treatment for their condition."

More information: www.thelancet.com/journals/lan… (14)70105-6/fulltext

add to favorites email to friend print save as pdf

Related Stories

Surgery beats chemotherapy for tongue cancer, study finds

Dec 26, 2013

Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University ...

Recommended for you

Study pinpoints microRNA tied to colon cancer tumor growth

4 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

Obesity tied to higher cancer risk for CRC survivors

5 hours ago

(HealthDay)—Colorectal cancer (CRC) patients who are overweight or obese when diagnosed appear to face a slightly higher risk for developing a second weight-related cancer, according to research published ...

User comments